Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Assets Average (2016 - 2025)

ImmunityBio (IBRX) has disclosed Assets Average for 11 consecutive years, with $460.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average rose 13.87% to $460.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $460.5 million, a 13.87% increase, with the full-year FY2024 number at $443.7 million, up 2.37% from a year prior.
  • Assets Average was $460.5 million for Q3 2025 at ImmunityBio, up from $352.9 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $468.4 million in Q4 2023 to a low of $215.4 million in Q1 2021.
  • A 5-year average of $363.1 million and a median of $357.6 million in 2022 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 59.47% in 2021, then dropped 24.13% in 2025.
  • ImmunityBio's Assets Average stood at $227.9 million in 2021, then skyrocketed by 56.96% to $357.6 million in 2022, then soared by 30.98% to $468.4 million in 2023, then dropped by 20.21% to $373.8 million in 2024, then increased by 23.22% to $460.5 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Assets Average are $460.5 million (Q3 2025), $352.9 million (Q2 2025), and $343.3 million (Q1 2025).